Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oxcarbazepine Extended Release (OXC XR) as Adjunctive Therapy in Pediatric Subjects With Refractory Partial Epilepsy

This study has been completed.
Information provided by (Responsible Party):
Supernus Pharmaceuticals, Inc. Identifier:
First received: June 9, 2009
Last updated: May 10, 2013
Last verified: May 2013
Study to evaluate the pharmacokinetics, safety, and tolerability of OXC XR as adjunctive therapy in pediatric subjects with refractory partial epilepsy.

Condition Intervention Phase
Drug: Oxcarbazepine
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multiple Dose, Open-Label, Multi-Center Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of OXC XR as Adjunctive Therapy in Pediatric Subjects With Refractory Partial Epilepsy

Resource links provided by NLM:

Further study details as provided by Supernus Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Examine the steady-state pharmacokinetics (PK) of OXC XR and to assess the safety and tolerability of repeated oral dosing of OXC XR in pediatric subjects with partial seizures.

Enrollment: 18
Study Start Date: June 2009
Study Completion Date: November 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Open Label Study
Drug: Oxcarbazepine
Open Label study
Other Name: NAP


Ages Eligible for Study:   4 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Able to provide written informed assent (IAF), as appropriate, with written informed permission (and informed consent (ICF) where required by regional laws or regulations) from the parent or legally-authorized representative (LAR).
  2. Male or female aged 4 to 17 years, inclusive, with a current diagnosis of partial onset seizures with or without secondarily generalized seizures as confirmed by the 1981 and 1989 International League Against Epilepsy Classifications).
  3. Currently receiving treatment with at least one and up to two AEDs, excluding oxcarbazepine and phenytoin. AED therapy must have been initiated more than one month prior to Visit 1 and doses must be stable for at least two weeks prior to Visit 1. A vagal nerve stimulator implanted for at least six months and with parameters unchanged for at least one month prior to Visit 1 is allowed and not considered to be an AED. Magnet use is allowed.
  4. No diagnosis of a progressive neurological disorder based on previous imaging.
  5. Weight within the 25 - 75 % weight-for-age percentiles based on the National Center for Health Statistics Growth Charts, and not less than 15.0kg.
  6. Able and willing to swallow whole tablets.
  7. Females of childbearing potential (FOCP) should either be sexually inactive (abstinent) for 14 days prior to the first dose, throughout the study and for four days following the last dose or, if sexually active, will be using one of the following acceptable birth control methods:

    1. Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) six months minimum;
    2. Intrauterine device in place for at least three months;
    3. Barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to the first dose, throughout the study and for four days following the last dose;
    4. Surgical sterilization of the partner (vasectomy for six months minimum);
    5. Hormonal contraceptives in addition to a barrier method (condom, diaphragm) with spermicide for at least 14 days prior to the first dose, throughout the study and for four days following the last dose.

Exclusion Criteria:

  1. A documented history of status epilepticus in the past year.
  2. Seizures secondary to illicit drug or alcohol use, infection, neoplasia, demyelinating disease, degenerative neurological disease, or central nervous system disease deemed progressive, metabolic illness, or progressive degenerative disease.
  3. Diagnosis or an electroencephalogram consistent with a diagnosis of seizure disorders other than partial epilepsy.
  4. Meets criteria for history of major depressive or manic episode, according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision.
  5. Any history of suicide intent and/or attempt.
  6. History or presence of clinically significant, chronic medical condition, especially those contraindicating antiseizure medication, (e.g., any neurological, gastrointestinal, endocrine, cardiovascular, pulmonary, hematological, immunologic, renal, hepatic or metabolic disease) that may affect the safety of the subject in the opinion of the Investigator.
  7. Use of oxcarbazepine or phenytoin within 10 days prior to first dose of SM.
  8. Use of felbamate with less than 18 months of continuous exposure prior to screening.
  9. Frequent need of rescue benzodiazepines (more than once in a 28 day period).
  10. Use of diuretics or other sodium-lowering medications within seven days prior to first dose of SM.
  11. History or presence of clinically significant laboratory, electrocardiogram (ECG), or vital sign abnormalities at screening that may affect the safety of the subject, in the opinion of the Investigator.
  12. Presence of potential hepatic function impairment as shown by, but not limited to, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times the upper limit of normal (ULN), or total bilirubin >1.5 times ULN.
  13. Presence of suspected impairment of renal function defined by serum creatinine ≥1.5 times ULN.
  14. History of substance abuse or dependence.
  15. Females who are pregnant or lactating.
  16. Previous known hypersensitivity to OXC or other related drugs, such as carbamazepine.
  17. Use of an investigational drug or device or participation in an investigational study within 30 days prior to the first dose of SM.
  18. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00918047

United States, Arkansas
Site 06
Little Rock, Arkansas, United States
United States, Florida
Site 03
Loxahatchee, Florida, United States
Palm Beach, Florida, United States
Site 10
Tampa, Florida, United States
United States, Maryland
Site 02
Rockville, Maryland, United States
United States, New York
Site 08
Lake Success, New York, United States
Site 05
Rochester, New York, United States
United States, Tennessee
Site 01
Kingsport, Tennessee, United States
United States, Texas
Site 07
San Antonio, Texas, United States
Sponsors and Collaborators
Supernus Pharmaceuticals, Inc.
  More Information

Responsible Party: Supernus Pharmaceuticals, Inc. Identifier: NCT00918047     History of Changes
Other Study ID Numbers: 804P107
Study First Received: June 9, 2009
Last Updated: May 10, 2013

Additional relevant MeSH terms:
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents processed this record on April 26, 2017